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Background: The majority of patients with acute myelogenous leukemia (AML) still die of their disease. In order to
improve survival rates in AML patients, new strategies are necessary to discover biomarkers for the detection and
targeted therapy of AML. One of the advantages of the aptamer-based technology is the unique cell-based
selection process, which allows us to efficiently select for cell-specific aptamers without knowing which target
molecules are present on the cell surface.
Methods: The NB4 AML cell line was used as the target cell population for selecting single stranded DNA
aptamers. After determining the affinity of selected aptamers to leukocytes, the aptamers were used to phenotype
human bone marrow leukocytes and AML cells in clinical specimens. Then a biotin-labelled aptamer was used to
enrich and identify its target surface protein.
Results: Three new aptamers were characterized from the selected aptamer pools (JH6, JH19, and K19). All of them
can selectively recognize myeloid cells with Kd in the low nanomole range (2.77 to 12.37 nM). The target of the
biotin-labelled K19 aptamer probe was identified as Siglec-5, a surface membrane protein in low abundance whose
expression can serve as a biomarker of granulocytic maturation and be used to phenotype AML. More importantly,
Siglec-5 expression can be used to detect low concentrations of AML cells in human bone marrow specimens, and
functions as a potential target for leukemic therapy.
Conclusions: We have demonstrated a pipeline approach for developing single stranded DNA aptamer probes,
phenotyping AML cells in clinical specimens, and then identifying the aptamer-recognized target protein. The
developed aptamer probes and identified Siglec-5 protein may potentially be used for leukemic cell detection and
therapy in our future clinical practice.
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Acute myelogenous leukemia (AML) is a heterogeneous
group of malignant hematopoietic neoplasms derived
from hematopoietic stem cells postulated to arise due to
mutations of genes that regulated the orderly prolifera-
tion, differentiation, and maturation of hematopoietic
cells. In the past two decades, scientific advances utiliz-
ing molecular techniques and cytogenetic detection have
yielded new insights into the genetic and biologic* Correspondence: liying@pathology.ufl.edu
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stated.features of acute leukemia. Despite these advances, the
majority of patients who suffered from AML still died of
their disease [1-3]. With the exception of a subtype of
AML, AML M3 (i.e. acute promyelocytic leukemia,
APL), we have not yet succeeded in translating our
scientific discoveries into more effective treatments for
the majority of AML patients. While therapeutic in-
tensification, improved supportive care, and bone mar-
row transplantation have led to gradual improvements
of outcome in children and younger adults with AML,
the overall survival rate approaches 50%. In older indi-
viduals (>55-60 years) and in secondary AML patients,
the outlook is more dismal with overall survival rates ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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favorable cytogenetic features.
Currently, immunophenotyping via immunohistochem-
istry and flow cytometric analysis plays a pivotal role in
the detection and diagnosis of AML. However, the surface
biomarkers currently used for immunophenotyping AML
are adapted from the advancement of immunology re-
search in the last several decades instead of being spe-
cifically developed for leukemic cell detection. While we
use these biomarkers in our daily practice to classify
leukemia into myeloid or lymphoid lineages, they nei-
ther identify the molecular events underlying the neo-
plastic processes nor provide adequate insight into the
aggressiveness or prognosis of these diseases. As a con-
sequence, many different leukemic variants become
grouped together under the same name due to the lack
of adequate biomarkers for effective stratification, des-
pite not representing the same exact disease by nature
or behavior [5,6]. In addition, when only a small number
of leukemic cells are present it is often difficult, if not
impossible, to determine the disease status due to their
immunophenotypic similarity to normal cells. This is
often the case following chemotherapy when minimal
residual leukemia is present. Therefore, a new strategy
using molecular aptamers is envisioned to discover bio-
markers and apply them in clinical practice to improve
therapeutic efficiency and the survival rate of AML
patients.
Molecular aptamers consist of single stranded DNA or
RNA that can recognize target proteins, peptides, and
other small molecules. Through a process called SELEX
(Systematic Evolution of Ligands by Exponential enrich-
ment) [7-11], DNA or RNA aptamers specific for a known
protein of interest can be selected from a random pool of
oligonucleotide sequences, and then used as diagnostic
and therapeutic reagents [12]. Traditionally, the targets
(most often proteins), in most instances, have to be identi-
fied first before specific molecular probes, including
monoclonal antibodies, can be developed. However, using
live cells from leukemic cell lines, we established a unique
cell-based selection process (Cell-SELEX) that allows for
the selection of aptamers that can recognize live leukemic
cells from patients [13]. Most importantly, the Cell-
SELEX method allows us to select a group of cell-specific
aptamers in a relatively short time period and selected
aptamers can readily be tested and verified in clinical
specimens, without knowing which target molecules are
present on the cell surface. Thus far, while many DNA or
RNA aptamers have been selected against various types of
cells, a few surface proteins targeted by individual apta-
mers of interest were identified [14], which is probably
due to the technical challenge in purification and identi-
fication of low-abundance membrane proteins [14]. The
few reported proteins identified through individualaptamer probes include pigpen from the rat endothelial
cell line YPEN-1 [15], Tenascin-C of U251 glioblastoma
cells [16], immunoglobulin heavy mu chain in Burkitt’s
lymphoma cells [17] and protein tyrosine kinase-7 (PTK7)
on CCRF-CEM T-cell acute lymphoblastic leukemic
cells [18].
In order to develop biomarkers for AML, we intended
to design a pipeline approach for biomarker discovery:
1) To employ the Cell-SELEX technique to select for
DNA aptamer probes against live leukemic cells; 2) To
test selected aptamers by phenotyping normal human
bone marrow cells or leukemic cells in clinical speci-
mens; 3) To identify target proteins on leukemic cell
surfaces with meaningful molecular signatures as dem-
onstrated with the aptamers. In this study, we selected
aptamers against NB4 AML cells. More importantly, with
biotin-labelled aptamers we were able to demonstrate that
the target protein for one of the new aptamers was a
member of the sialic-acid-binding immunoglobulin-like
lectins (Siglecs). Then the aptamer recognizing Siglec-5
was used to detect small numbers of AML cells in human
bone marrow specimens.
Material and methods
Cell culture and Reagents
NB4 and HL60 human leukemic cell lines were obtained
from ATCC (American Type Culture Collection, Manassas,
Virginia) and were cultured in RPMI 1640 medium
(Thermo Scientific HyClone, South Logan, Utah) supple-
mented with 10% fetal bovine serum (FBS) (heat inacti-
vated, Thermo Scientific HyClone, South Logan, Utah),
and antibiotics (100 units/ml penicillin-Streptomycin from
Fisher BioReagents, Fairlawn, NJ). Before binding to apta-
mers, cells were washed with phosphate-buffered saline
(PBS). The buffer used for aptamer binding and selection
was prepared by adding 4.5 g/L glucose, 5 mM MgCl2,
0.1 mg/ml yeast tRNA (Fisher BioReagents, Fairlawn, NJ,
USA) and 1 mg/ml Bovine Serum Albumin (BSA) (Fisher
BioReagents) into Phosphate buffered saline (PBS) [13].
The used fluorochromes include allophycocyanin (APC),
fluorescein isothiocyanate (FITC), phycoerythrin (PE), and
peridinin chlorophyll protein (PerCP).
Cell-SELEX procedures for aptamer selection
HPLC purified libraries (Sigma-Aldrich, St. Louis,
MO) contain a segment of randomized sequence of
50 nucleotides (nt) flanked by PCR primer hybridi-
zation sites (5′-GACGCTTACTCAGGTGTGACTCG-
50 nt-CGAAGGACGCAGATGAAGTCTC-3′). Biotinylated
PCR-primers were used in the PCR reactions for the
synthesis of biotin-labelled DNA molecules. After heat
denaturation at 95°C for 5 min, the denatured DNAs
were placed on ice immediately and the biotinylated
strands were separated from the complement strands
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The selection processes were performed similarly as
described before [13,19]. 20 nmoles of synthesized single
stranded DNA pool were dissolved in 1 ml of binding
buffer and used for the first round selection. 100–200
pmoles of pool dissolved in 400 μL binding buffer were
used for the remaining rounds of selection. The DNA
pools were denatured by heating at 95°C for 5 min and
placed on ice for 10 min before binding. The single
stranded DNA pool was incubated with 1–2 × 106 target
(NB4) cells on ice for 1 hr. After washing, the bound
DNAs were eluted by heating at 95°C for 5 min in
400 μL of 2 mM Tris–HCl buffer (pH 8.0). The eluted
DNAs were amplified by PCR (Taq-polymerase and
dNTP’s were obtained from Fisher (Fairlawn, NJ)) for
25–30 cycles of 0.5 min at 94°C, 0.5 min at 60°C, and
0.5 min at 72°C, followed by 5 min at 72°C. The
amplified sense DNA pool used for the next round
selection was separated from antisense PCR products by
streptavidin-coated magnetic beads. After 8–20 rounds
of selection, biotinylated selected DNA pools or single
stranded DNA control were bound to NB4 cells on ice
for 30 min, washed twice with cold PBS and then incu-
bated with 5 μL PE-streptavidin (0.5 mg/ml, Becton
Dickinson, NJ) on ice for 30 min. After washed twice
with PBS, the NB4 cells were subject to flow cytometry
analysis. After the selected pool showed significantly
higher fluorescence signals than the unselected one (see
Additional file 1: Figure S1), selected pool was PCR-
amplified using unlabeled primers, cloned into pPCR-
Script Amp SK(+) vector with PCR-Script Amp Cloning
Kit (Agilent Technologies, San Diego, CA) and trans-
formed into Escherichia coli (DH5α), as described in
previous studies [13,19]. 100 white colonies were picked
and grew for minipreprations of plasmid DNA with
QIAprep Spin Miniprep Kit (Hilden, Germany). The
DNA sequences were determined by the DNA sequen-
cing facility at the Interdisciplinary Center for Biotech-
nology Research, University of Florida. DNA sequences
that were present in more than two clones were consid-
ered as aptamer candidates.
Flow cytometric analysis of aptamer binding to target
cells
Biotin-labelled, selected single stranded DNA pools or
individual aptamers of interest were incubated with 5 ×
105 cells in 200 μL of binding buffer with 0.1% NaN3 on
ice for 30 min. Cells were washed twice with 4 ml of
PBS buffer and incubated with 5 μL PE-streptavidin
(0.5 mg/ml, Becton Dickinson, NJ) for 30 min. Biotin-
labelled unselected library was used as a negative control.
The cells were washed once and cell-bound fluorescence
was determined with a FACScan or FACSCalibur flowcytometer (Becton Dickinson, NJ) by counting 20,000-
50,000 events. The FITC, PE and PERCP were activated
by blue laser (488 nm) and APC by red laser (635 nm).
Fluorescence-labelled monoclonal antibodies were used
with aptamers to define lineages of bone marrow leuko-
cytes and leukemic cells in clinical specimens. To deter-
mine the binding affinity of selected aptamers, all
experiments for the aptamer binding assay were repeated
2–4 times. The GraphPad Software (San Diego, CA, USA)
was used to analyze the data for obtaining the equilibrium
dissociation constants (Kd) of the fluorescent aptamers
and the 95% confidence interval.
Clinical sample preparation and testing
All clinical samples were submitted for pathological
evaluation to the Shands Hospital Hematopathology
Laboratory, University of Florida. The studies were ap-
proved by the University of Florida Institutional Review
Board. The presented data include thirty-six cases of
AML. Ten cases of non-malignant human bone marrow
were also used for the studies.
Erythrocytes in all bone marrow samples specimens
were lysed as described before [20]. Human bone mar-
row or leukemic cells were immunophenotyped with
thirty fluorochrome-conjugated monoclonal antibodies
in our clinical flow cytometry panels [20], for immuno-
phenotyping mature or immature granulocytes, mono-
cytes, blasts and lymphocytes so that we can determine
how to selectively gate the cell population of interest.
The data analysis was performed using FCS Express soft-
ware (De Novo Software, Los Angeles, CA, USA, http://
www.denovosoftware.com). Initial cell subpopulations were
established using the levels of CD45 expression and side-
scatter (SSC) properties [21,22]. After defining immu-
nophenotypes of leukemic cells, antibodies for CD45,
CD34, CD117, CD33, HLA-DR, CD64 or CD14 (Becton
Dickinson, NJ) were used to select cells of interest to
determine fluorescence levels of bound aptamers for
individually gated subpopulations.
Statistical analyses
GraphPad Software was used for statistical analyses. The
One-way Analysis of Variance (ANOVA) or T test was
used to compare fluorescence levels of aptamers bound
on the different cell populations. Unless stated other-
wise, results were given as mean ± standard deviation
(SD) and the P values were also given for comparison as
necessary.
Protease treatment for cells
NB4 cells (5 × 106) were washed with PBS and then
incubated with 1 ml of 0.25% trypsin/0.1% EDTA in
Hank’s buffered salt solution (HBSS) (Thermo Scientific
HyClone, Pittsburgh, PA) at 37°C for 10 min. FBS was
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PBS, the treated cells were used for aptamer-binding
assays as described earlier.
Enrichment and identification of the aptamer-bound
target protein
A total of, 8 × 108 NB4 cells in the active growing phase
were harvested, and used as target cells for aptamer K19
binding followed by enrichment of the aptamer-bound
target protein. The NB4 cells were pre-incubated with
8 ml of RPMI media containing 1 mg of heat-denatured
Herring Sperm DNA (Promega) at 4°C for 15 min to
block potential nonspecific binding of the aptamer to
the cells. The cells were then incubated in the binding
buffer with or without biotin-labelled aptamer K19 (at
the final concentration of 300 nM) and the binding was
performed without any aptamers was used as a negative
control. To determine the specificity of aptamer binding,
an additional negative control was made by pre-incubating
the cells with 300 nM of the unlabeled K19 aptamer for
1 hr prior to the binding of the biotin-labelled aptamer.
After binding, the cells were washed three times with
PBS to remove the unbound aptamer. A small aliquot of
each cell sample (5 × 105 cells) was taken, and analysed
by flow cytometry with PE-streptavidin to monitor the
aptamer binding.
The aptamer-bound or control cells were then lysed in
10 ml of lysis buffer containing 10 mM HEPES pH 7.4,
150 mM NaCl, 1% Triton X-100 and 1 mM EDTA plus
HaltTM protease inhibitor cocktail (Thermo Scientific
Pierce, Pittsburgh, PA) on ice for 15 min. After centrifu-
gation at 14000 g for 15 min, the supernatant was incu-
bated with 1 mg (100 μl) of magnetic streptavidin beads
at 4°C for 30 min to capture the protein-aptamer com-
plexes. The beads with bound aptamer-protein com-
plexes were then collected on an EasySep magnet stand
(Stemcell Technologies, Vancouver, BC, Canada) and
washed five times with 15 ml of the lysis buffer. The
enriched proteins were heated for elution and separated
by 11% SDS-polyacrylamide gel electrophoresis (SDS-
PAGE). The gels were then silver-stained with the Pierce
Silver Stain Kit (Thermo Scientific Pierce, Rockford, IL).
The aptamer-specific protein bands were excised and
trypsin-digested in situ [23] and analysed by QSTAR
LC-MS/MS and a MASCOT database search at the
Interdisciplinary Center for Biotechnology Research
Mass Spectrometry Core Facility, University of Florida.
Studies of aptamer-antibody competition
Fluorescein-conjugated mouse monoclonal anti-human
Siglec-5 (Clone 194128, R&D Systems, Minneapolis,
MN, USA) and biotin-labelled or unlabeled K19 apta-
mers were used in the competition studies. Competition
experiments were carried out in two ways: 1) NB4 cells(2 × 105) were incubated with 300 nM of the unlabeled
K19 aptamer or a control aptamer in 100 μL of binding
buffer at 4°C for 45 min. After washing with PBS to re-
move the unbound aptamers, cells were incubated with
5 μg/ml fluorescein-conjugated anti-Siglec-5 antibody or
control IgG1 antibody in 50 μL of PBS with 0.5% BSA at
4°C for 45 min. After washing off of the unbound anti-
bodies, the cells were analysed by flow cytometry. 2) The
NB4 cells were incubated with the anti-Siglec-5 or the
control antibody and then with the biotin-labelled
aptamer K19 or control aptamers. After PBS washing,
PE-streptavidin was added followed by flow cytometric
analysis as described earlier.
Non-Radioactive Cell Proliferation Assay
CellTiter 96® Non-Radioactive Cell Proliferation Assay
Kit (Promega, Wisconsin) was used to determine viable
cell numbers after NB4 cells were incubated with various
amounts of aptamer-streptavidin-saporin complexes or
mixtures of aptamer and unlabeled saporin. After incu-
bation for 72 hours, the assay is performed by adding a
premixed, optimized Dye Solution to culture wells of a
96-well plate. In 4-hour incubation, living cells convert
the tetrazolium component of the Dye Solution into a
formazan product. The Solubilization/Stop Solution then
was added to the culture wells to solubilise the formazan
product, and the absorbance at 570 nm is recorded
using a 96-well plate reader.
Results
Using Cell-SELEX for selection of aptamers bound to NB4
cells
Cultured AML NB4 and HL60 cell lines have been used
for aptamer selection, and aptamers selected against
HL60 cells can recognize monocytic cells [19]. Because
of previous unsuccessful attempts to select aptamers
against NB4 cells, we focused on the viability of the cul-
tured cells used for aptamer selection. Through careful
optimization, we critically improved the cell culture
conditions necessary to maintain NB4 cells in the active
proliferation phase. The use of cells in the active proli-
feration phase improved the cells viability during the
aptamer selection procedures, which in turn reduced
nonspecific aptamer binding caused by dead cell frag-
ments or debris. As a result, we were able to select a
panel of aptamers for NB4 cells. In addition, we signifi-
cantly reduced the time period needed for Cell-SELEX,
and were able to obtain the aptamers with approxi-
mately eight rounds of selection. 10 aptamer candidates
were obtained through sequencing 100 individual clones
and we chose three representative aptamers (JH6, JH19
and K19) (Table 1) for further studies because the three
new aptamers showed much better recognition to NB4
cells than to HL60 cells, and the bound aptamers
Table 1 Sequences and binding affinity of selected aptamers
Aptamers Kd (nM) Confidence interval (nM) (95%) Aptamer sequences*
JH6 2.77 0.69-4.85 5′-GTACGCCGCAAGACGAGTTGTGTATAAGCCGGC-3′
JH19 7.57 4.13-11.02 5′-AGGTGTGACTCGATCTGTGGGGGTT GGGGGGTGGTTTTTCGGAA-3′
K19 12.37 7.79-16.94 5′-AAGGGGTT GGGTGGGTTT ATACAAATTA ATTAATATTGTATGGTATATTT-3′
*All aptamers have two short sequences (5′GACGCTTACTCAGGTGTGACTCG3′ and 5′CGAAGGACGCAGATGAAGTCTC3′) attached to the 5′ and 3′ ends, respectively,
of the aptamer sequences shown above. The short sequences at 5′ and 3′ ends were used for PCR amplification.
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scence intensity compared to the DNA library control
(Figure 1a). We then determined the affinity of the
three aptamers to NB4 cells. All the three aptamers
have high affinity for NB4 cells with calculated Kd of
2.77 nM for JH6, 7.57 nM for JH19 and 12.37 nM for
K19 (Figure 1b and Table 1).Figure 1 Aptamer recognition of cultured NB4 and HL60 leukemic ce
leukemic cells. Individually synthesized biotin-labelled aptamers and PE-stre
ability to recognize NB4 and HL60 cells. Single-stranded library DNA was us
is illustrated as the following: negative control (black); JH6 (green); JH19 (bl
buffer was 150 nM. (b). Determination of the aptamer binding affinities to
used for the binding assays. The background binding was measured by us
geometric means of bound aptamers was determined by flow cytometry. T
were obtained by fitting the dependence of specific binding fluorescence
Y = Bmax*X/(Kd + X) using the GraphPad Software (San Diego, CA, USA) asThe selected aptamers can differentially recognize
myeloid cells in normal human bone marrow specimens
Because all three aptamers were selected against the
AML NB4 cell line, we tested whether the selected apta-
mers (JH6, JH19 and K19) have an ability to recognize
different types of leukocytes in human bone marrow
specimens. While no binding on lymphocytes was seen,lls. (a). Comparison of aptamer recognition of cultured NB4 and HL60
ptavidin were analyzed with flow cytometry in order to compare their
ed as a negative control. The binding of selected aptamers with cells
ue); K19 (red). The final concentration of these aptamers in binding
NB4 cells. The biotin-labeled aptamers and PE-labeled streptavidin were
ing unselected single-stranded library DNA. The fluorescence intensity
he equilibrium dissociation constants (Kd) of the fluorescent ligands
intensity on the concentration of the ligands to the Equation
described in previous studies [13].
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(6 to 17 folds of fluorescence intensity over background)
on mature and immature granulocytes and monocytes
(Figure 2). The results suggest that the three aptamers
may recognize myeloid-specific surface markers. The
bound aptamer K19 had higher fluorescence intensity on
granulocytes, monocytes, and NB4 cells than bound
aptamers JH6 and JH19 (Figures 1 and 2). In addition, all
three aptamers had low, but statistically significant, levels
of binding on CD34(+) early hematopoietic precursors
(Figure 2).
The selected aptamers can differentially recognize
leukemic cells from AML non-M3 and AML M3 cases
Because the three aptamers recognized maturing granulo-
cytes and monocytes better than CD34(+) early progeni-
tors, we separated AML clinical specimens into three
groups: 1) AML non-M3 CD34(+); 2) AML non-M3
CD34(−); and 3) AML M3. We then determined if apta-
mers JH6, JH19, and K19 could differentially recognize
any groups of AML cases. While these aptamers showed
low levels of reactivity on normal CD34(+) progenitors, all
three aptamers can recognize both CD34(+) and CD34(−)
cells of AML non-M3 cases with the median values of
fluorescence intensity being ~8 to 30 fold higher than
those of background binding (Figure 3). However, the
levels of the three aptamers bound on AML non-M3 cases
varied significantly, and there was no statistical signifi-
cance in aptamer binding levels between the normal
CD34(+) cells and leukemic cells from AML non-M3
cases. Critically, all three aptamers had much lower levels
of binding on leukemic cells of AML M3 cases than nor-
mal CD34(+) early progenitors or leukemic cells of AML
non-M3 cases. These differences were statistically signifi-
cant (Figure 3).Figure 2 Recognition of normal bone marrow leukocytes by aptamer
or single-stranded negative control DNA on normal human bone marrow c
was determined by flow cytometry. Fluorescence intensity is shown as me
of < 0.05, < 0.01, and < 0.001, respectively.Using biotin-labelled K19 aptamers to enrich and identify
its target protein
In order to determine if the targets of the aptamers may
represent surface proteins or moieties associated with
surface membrane proteins, we treated NB4 cells with
trypsin before binding the aptamers on cells. As shown
in Figure 4a, the binding sites of aptamers JH6, JH19
and K19, as indicated by the fluorescence intensity of
bound aptamers, were partially or almost completely
abolished by 10 min of trypsin digestion. These results
suggest that the target molecules recognized by these
aptamers may be directly or indirectly related to surface
proteins anchored on the cell membrane.
Since aptamer K19 bound NB4 cells demonstrate
relatively higher fluorescent intensity, suggesting more
abundant aptamer K19 binding sites as compared to the
cells bound with aptamers JH6 and JH19, and three
aptamers showed similar binding patterns when applied
to bone marrow CD34(+) cells, granulocytes and mono-
cytes, we focused on identification of the protein target
associated with the binding site of aptamer K19. Flow
cytometric analysis is a very sensitive technology, and we
estimated that there were only a few hundred aptamer
K19 binding sites on individual NB4 cells when we
compared the fluorescence intensity of K19 to those of
PE-beads (QuantiBRITE PE, Becton Dickinson), which
are designed to estimate the number of bound antibody
molecules per cell.
To verify the specific binding of aptamer K19 during
target protein enrichment, we used a negative control, in
which unlabeled aptamer K19 was used to block the
binding of biotin-labelled aptamer K19 to NB4 cells.
Flow cytometric analysis of small aliquots of the aptamer-
bound cell samples, which were made to enrich target
proteins, demonstrated that the unlabeled aptamer cans JH6, JH19, and K19. The fluorescence intensity of bound aptamers
ells, including lymphocytes, granulocytes, monocytes, and CD34+ cells
an ± standard deviation, and “*”, “**”, and “***” represent the P values
Figure 3 Comparison of aptamer recognition of AML leukemic
cells and non-malignant CD34(+) cells. The AML cases were
separated into three groups: 1) CD34(+) AML non-M3; 2) CD34(−)
AML non-M3; and 3) AML M3. The fluorescence levels of bound
aptamers or single-stranded negative control DNA were determined
by flow cytometry. The fluorescence intensity levels of bound
aptamers (folds over background) were calculated (a, JH6; b, JH19
and c, K19). Individual values for each aptamer bound on each case
are shown as individual symbols, and mean ± standard deviation of
individual groups are also shown. The P values are given as “*”,
“**”, and “***” representing the P values of < 0.05, < 0.01, and
< 0.001, respectively.
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tive of the binding specificity of aptamer K19 (Figure 4b).
The protein-aptamer complexes were extracted with
the buffer containing 1% Triton X-100, captured using
streptavidin-coated magnetic beads, and separated by
SDS-PAGE. We then applied silver-stain for protein de-
tection (Figure 4c). Compared with the negative controls
(lane 1, without aptamer added and lane 2, blocked by
unlabeled aptamer K19), several apparent K19-specific
protein bands were shown in lanes 3 and 4. These bands
were excised for further trypsin treatment, and analysed
by mass spectrometry (MS). It is noteworthy that SDS-
PAGE analyses were run under both reducing and non-
reducing conditions, and the smear band at 130–140 kDa
obtained under the non-reducing condition was reprodu-
cibly detected (Figure 4c, arrow).
The MS data of peptides were used to search the
MASCOT database in order to identify possible protein
candidates. The candidate protein hits (~20) include
many RNA or DNA binding proteins, intracellularly
localized soluble proteins such as lysozyme C, and con-
taminated keratins. The only cell surface protein identi-
fied on the list was Sialic acid-binding Ig-like lectin 5
(Siglec-5). The MS data showed 5 unique peptides iden-
tified as fragments of Siglec-5. The sequences of identi-
fied peptides are marked on the Siglec-5 sequence as
shown in Figure 5. Siglec-5 exists as a disulfide-linked
dimer of ~140 kDa [24,25], which is in agreement with
the size of the K19-bound 130–140 kDa protein band
identified on SDS-PAGE under the non-reducing condi-
tion (Figure 4c, arrow).Aptamer K19 and anti-Siglec-5 antibody can compete
against each other for the binding sites on the NB4 cells
To confirm that Siglec-5 is the protein target of the
aptamer K19, we carried out the competition experiment
using a fluorescein-conjugated anti-human Siglec-5 anti-
body. As shown in Figure 6a and c, the aptamer K19
and the Siglec-5 antibody can compete against each
Figure 4 Using biotin-labeled K19 aptamer to enrich its target protein. (a). Effect of trypsin pre-treatment on binding of aptamers to NB4
cells. NB4 cells were treated with trypsin at 37°C for 10 min. The binding of selected aptamers with trypsin-treated NB4 cells is illustrated: JH6 (a1);
JH19 (a2); and K19 (a3). The final concentration of these aptamers in binding buffer was 300 nM. The background binding was measured by using
biotinylated single-stranded negative control DNA. (b). Binding competition of biotinylated-K19 to NB4 cells by the unlabeled K19 aptamers. NB4
cells were pre-incubated with the unlabeled K19 aptamers (300 nM) for 1 hr prior to binding of the biotin-labeled aptamers. The fluorescence
intensity of bound aptamers is shown by the histograms (blue, binding of biotinylated K19; red, binding of biotinylated K19 after blocking by
non-labeled K19). The background binding was measured by using biotinylated single-stranded negative control DNA. (c). Silver-stained
polyacrylamide gel electrophoresis (SDS-PAGE) separating the proteins captured by aptamer K19. NB4 cells were pre-incubated with or without
the unlabeled aptamer K19 for 1 hr prior to binding of the biotin-labeled aptamers. The NB4 cells were then lysed. The protein-aptamer DNA
complex(s) were captured by the magnetic streptavidin beads, and were then separated by SDS-PAGE followed by silver staining for detection of
characteristic protein bands. Lane M, molecular markers; Lane 1, proteins captured with streptavidin beads (no aptamer); Lane 2, proteins captured
by biotin-aptamer K19 after blocking by unlabeled aptamer K19; Lanes 3 and 4, protein captured with biotinylated aptamer K19.
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http://www.jhoonline.org/content/7/1/5other for the binding sites on the NB4 cells. In contrast,
the control aptamer E10, which can also bind to NB4
cells (unpublished results), does not display any compe-
tition with the Siglec-5 antibody (Figure 6b and d), and
the reactivity of aptamer K19 toward NB4 cells was notaffected by isotype control antibodies (Figure 6a). Thus,
we confirmed that Siglec-5 is the targeted protein recog-
nized by aptamer K19, and that the binding site of apta-
mer K19 on the Siglec-5 protein may be sterically close
to the epitope bound by the Siglec-5 antibody.
Figure 5 The sequences of Siglec-5 protein and peptides recovered by mass spectrometric analysis of aptamer K19-enriched proteins.
The Ig-like V-type domain and two Ig-like C2-type domains of Siglec-5 are underlined while the signal peptide, the transmembrane region, and
the immunoreceptor tyrosine-based inhibitory (ITIM) motif are marked with dotted underlines. The peptides identified by mass spectrometry are
highlighted by bordering.
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maturation and AML cell detection as well as be used as
a potential target for leukemic cell growth inhibition
Siglec-5 was reported to be expressed on granulocytes
[26], but its expression during granulocytic or monocytic
maturation has not been well characterized. Since apta-
mer K19 recognized maturing granulocytes much better
than CD34(+) early progenitors in normal human bone
marrow (Figure 2), we further determined whether its
binding sites (i.e. Siglec-5 protein levels) on granulocytes
vary during granulocytic maturation. By flow cytometric
analysis, we separated maturing granulocytes or mono-
cytes into three subsets: early stage, immediate stage,
and matured stage, according to the expression levels of
CD13 and CD11b for granulocytes and CD64 and CD14
for monocytes (Figure 7, left panel) [27-29]. We then
determined the fluorescence levels of aptamer K19
bound on each subset. Compared with the negative con-
trol, the fluorescence intensity of bound aptamer K19
on granulocytes gradually increased during granulocytic
maturation (Figure 7, right panel), indicating progres-
sive up-regulation of Siglec-5 levels during granulocytic
maturation. However, persistently high levels of Siglec-5
expression were observed on both CD64(+)/CD14(−)
immature and CD64(+)/CD14(+) mature monocytes.
Because Siglec-5 is overexpressed in a subset of AML
cells, we selected an AML case with relatively high
levels of Siglec-5 expression, and spiked small numbers
of the AML cells into a normal human bone marrow
specimen. Then, based on the differential expression levelsof Siglec-5 on normal CD34(+) cells and CD34 (+)
leukemic cells, we used aptamer K19 to aid in the de-
tection of AML cells mixed into a normal bone mar-
row specimen (Figure 8). Additionally, to demonstrate
Siglec-5 can be a potential biomarker for targeted
therapy, we tested biotinylated Siglec-5 aptamer K19
and saporin-cross-linked to streptavidin (SA-SAP) for
inhibiting NB4 cell proliferation in vitro. Compared
with unlabeled saporin (SAP) (Figure 9a) or the biotiny-
lated single stranded DNA control (Figure 9b), the
Siglec-5 aptamer K19 can enhance the toxicity of SA-
SAP to NB4 cells with an estimated IC50 of 25 to 50
nM. The enhanced toxic effect of biotinylated K19 apta-
mer can be blocked by non-labelled aptamer K19,
indicating that the enhanced cell toxicity is mediated
through the specific binding to surface Siglec-5 proteins
(Figure 9c).Discussion
The molecular characteristics of leukemic cells, especially
at the proteomic level, are critical for understanding
leukemia pathogenesis and designing targeted therapy. In
the last several decades, proteomic analysis has been per-
formed to advance the discovery of diseased cell-specific
protein biomarkers, but so far only a few AML biomarkers
have been introduced into clinical practice for AML
detection and therapy. Currently, we still lack effective
biomarkers for AML diagnosis and targeted therapy.
Thus, our intent in this study is to develop new
Figure 6 Competition binding assays of aptamer K19 and anti-Siglec-5 antibody. For blocking aptamer binding with antibodies, NB4 cells
were pre-incubated with anti-Siglec-5 or isotype control antibodies before binding to biotin-labelled aptamers K19 (a) or E10 (b). The fluorescence
intensities of bound aptamers were determined by flow cytometry. Similar approaches were employed with aptamers K19 (c) or E10 (d) used to block
binding of the FITC-anti-Siglec-5 antibody on NB4 cells. The FITC-isotype control (IgG1) was used as a negative control for specific antibody binding.
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on AML cells.
Membrane proteins function as adhesion-anchors,
receptors, transporters and enzymes that play roles in
various physiological processes, and their dysregulation
may contribute to the pathogenesis of many disease
processes, including AML. It is estimated that 20–35% of
the mammalian genome encodes membrane proteins
[30]. However, membrane proteins remain mostly under-
represented in the proteomic analysis due to technical
challenges. Proteomic studies, using mass spectrometry-
based technology, aim at identifying individual proteins so
that an assay, most often antibody-based, can be developed
for a specific protein. By contrast, the Cell-SELEX ap-
proach produces a group of cell-specific aptamers that can
be verified in clinical specimens without purified pro-
teins or even knowledge of their protein targets. Theselected aptamers can easily be labelled for flow cytome-
try or image analysis of cells in clinical specimens. If
one of the aptamer probes detects a surface marker of
interest, the specific aptamer probe can be used to en-
rich and purify the target protein, such as aptamer K19
and its target Siglec-5. It should be noted that our stud-
ies do not seek to compare the capability of aptamers
with antibodies. Numerous high quality monoclonal anti-
bodies have been produced for isolated proteins. However,
it is difficult to make antibodies when we do not know the
target proteins on tumor cells.
We used HL-60 and NB4 human leukemic cell lines
for our experiments, and the two cell lines are closely
related. While both can differentiate under chemical
induction, only the NB4 cells originated from AML M3,
and carry the t(15;17) chromosome translocation [31-33].
By using these two leukemic cell lines, we can address
Figure 7 Using Siglec-5 as a biomarker for granulocytic different maturation in human bone marrow. Leukocytes from normal bone
marrow aspirates were incubated with aptamer K19 or the single-stranded negative control DNA. (a). Siglec-5 expression of maturing granulocytes.
The granulocyte population was first identified using levels of side-scattered light (SSC) in combination with the fluorescence intensity of CD45. Then,
maturing granulocytes were separated into three subsets according to the expression levels of CD13 and CD11b (left panel): early stage (yellow),
immediate stage (purple), and matured stage (green). Fluorescence intensity (PE) of the granulocyte subsets bound with single stranded DNA control
(middle panel) or aptamer K19/Siglec-5 (right panel) is shown in relation to fluorescence levels of CD11b (APC). (b). Siglec-5 expression of maturing
monocytes. The mature and immature monocytes were first identified using levels of side-scattered light (SSC) in combination with the fluorescence
intensity of CD64. Then, maturing monocytes were separated into three subsets according to the expression levels of CD64 and CD14 (left panel): early
stage (yellow), immediate stage (teal) and matured stage (fuchsia). Fluorescence intensity (PE) of the monocyte subsets bound with single-stranded
negative control DNA (middle panel) or aptamer K19/Siglec-5 (right panel) is shown in relation to fluorescence levels of CD14 (APC).
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DNA aptamers that are capable of detecting differences
in surface protein expression between two closely rela-
ted leukemic cell lines (HL60 and NB4)? B). Can these
selected aptamers be further used on clinical specimens
for phenotyping AML and identifying new biomarkers?
C). Can the newly identified biomarker be used to aid
the detection of AML cells in human bone marrow
specimens?
As a result, we used NB4 leukemic cells to select and
characterize three new DNA aptamers (JH6, JH19, andK19), which have more binding sites on NB4 cells than
on HL60 cells. This is in contrast to the aptamer KH1C12
previously selected from HL60 cells, which selectively
recognized HL60 cells [19]. Gene expression profiling
studies showed that NB4 and HL60 cell lines had the most
closely related profiles of mRNA expression [33]. Thus,
our results with aptamers selected against NB4 and those
previously selected against HL60 cells indicate that it is
possible to select aptamers capable of detecting differences
in surface protein expression between two closely related
leukemic cell lines.
Figure 8 Using Siglec-5 as a biomarker to detect low levels of AML cells in human bone marrow specimen. A representative AML bone
marrow (left panels in a. and b.) and normal bone marrow (NOR BM) (right panels in a. and b.) case are shown. In addition, the AML specimen is
diluted with normal bone marrow cells (middle panels in a. and b.), and the final AML cell fraction was approximately 1.6%. CD34(+) cells in three
samples are gated selectively according to the levels of CD34 and SSC (a.), and the expression of Siglec-5 on CD34(+) cells is displayed in (b.)
The CD34(+) leukemic cells (red dots in b.) have higher levels of Siglec-5 than normal CD34(+) cells in normal bone marrow (blue dots in b).
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leukemic cells, compared with those on CD34(+) progeni-
tors in normal bone marrow specimens, vary significantly
among different AML cases (Figure 3). The findings are
likely reflective of the heterogeneity of disease in the AML
group. While the overall fluorescence levels of bound
aptamers between the CD34(+) normal progenitors and
AML non-M3 groups are not statistically significant,
subsets of AML non-M3 cases may overexpress one or
more surface biomarkers that can be recognized by
aptamers. The heterogeneity of AML requires great ef-
fort and resources in order to develop useful bio-
markers for its detection and treatment, but we can
also use the heterogeneity of biomarker expression for
diagnosis or targeted therapy. If an AML case over-
expresses one or more surface biomarkers that can
be recognized by aptamers (e.g. Siglec-5 in Figure 8),
the aptamer probes may become useful tools for de-tecting the minimal residual disease of AML after
chemotherapy.
Despite their selection from NB4 cells derived from a
case of AML M3 and their ability to recognize maturing
granulocytes and monocytes well (Figure 2), all three
aptamers show relatively lower levels of binding to AML
M3 (Figure 3). Significant down-regulation of normal
myeloid markers may occur on AML M3 cells in clinical
specimens, and one well-known example is CD15. Like
CD15, the aberrantly down-regulated expression of apta-
mer target proteins, including Siglec-5 in AML M3,
makes it possible for us to use them as biomarkers to
differentiate between AML non-M3 and AML M3 cases
in clinical practice. Conversely, if AML cells in a clinical
specimen show high levels of reactivity to the three apta-
mers, the case is unlikely to represent AML M3.
The human, CD33-related, sialic acid binding,
immunoglobulin-like lectins (CD33rSiglecs) comprise a
Figure 9 Using Siglec-5 aptamer K19 to enhance the saporin toxicity for inhibiting NB4 cell proliferation in vitro. Various concentrations
of biotinylated-aptamer K19 (Biotin-K19) or biotinylated single-stranded negative control DNA (Biotin-SS DNA) and streptavidin-saporin (SA-SAP) or free
saporin (SAP) were mixed, and were then incubated with NB4 cells (a and b). The non-biotinylated aptamer K19 (K19) was used to block the binding
of biotin-K19 to NB4 cells (c). The viable cells were then measured in 72 hours. The experiments were performed in triplicates, and the data is shown
as fractions of the control groups. The P values are given as “*” or “**” representing the P values of < 0.05 or < 0.01, respectively.
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entially expressed on leukocytes. The aptamer K19,
which recognizes Siglec-5, can recognize granulocytes
and monocytes, with no significant binding to bone
marrow lymphocytes (Figure 2). In addition, with
aptamer K19 we demonstrated relatively low levels of
Siglec-5 on CD34(+) progenitor cells in normal bone
marrow (Figure 2), and up-regulated Siglec-5 during the
granulocytic maturation (Figure 7). These results are
consistent with previously reported results that Siglec-5
expression was up-regulated later than CD33 during
in vitro myeloid differentiation of CD34(+) cells purified
from cord blood [26].
CD33 has been used as one of the common markers
of AML. The antibody against CD33, gemtuzumab
(Mylotarg™), has been tested for the treatment of AML,
and was reported to be effective at inducing remissions
in about 25-30% of relapsed AML patients despite its
reversible toxicity on normal myeloid cells [34]. Due to
the restricted expression of CD33 on different leukocyte
cell types, other members of the CD33rSiglecs family,
including Siglec-5, have also been explored as targets for
cell-directed therapies of AML [35]. It was shown that
anti-Siglec-5 antibody linked with saporin toxin induced
cell killing in U937 human leukemic cells [36]. Our stu-
dies show that the Siglec-5 aptamer K19 can compete
with anti-Siglec-5 antibody for binding to NB4 cells
(Figure 6), and through Siglec-5 proteins it can also me-
diate uptake of Saporin to inhibit NB4 cell proliferation
in vitro. The published results of immunotoxin studies
were performed with antibodies directly conjugated to
toxin ([37,38]), and it should be noted that Saporin is
linked to streptavidin in our studies rather than directly
conjugated to aptamer K19. Therefore, the efficiency ofaptamer-mediated up-take of saporin might be low. In
these studies, our intent is to demonstrate the potential
of Siglect-5 and its aptamers, and it is necessary to per-
form further optimization of aptamers and aptamer-toxin
conjugates in order to determine whether Siglec-5 and its
aptamer can truly be used as a biomarker for detection
and targeted therapy of AML.
In summary, in this reported study, we have demon-
strated a pipeline approach for biomarker discovery. We
first employed the Cell-SELEX technique to select DNA
aptamers that can be used as molecular probes to pheno-
type normal hematopoietic cells and AML cells. We then
used one of the aptamers to enrich and identify its target
protein on the surface of leukemic cells. Finally, we dem-
onstrated that the identified biomarker (Siglec-5) can aid
in the detection of AML cells at low concentrations, and
can potentially mediate targeted therapy of AML cells.
This strategy developed with leukemic cells should be
applicable to other types of cancer to facilitate biomarker
discovery and targeted cancer therapy.Additional file
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